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Serum-free insulin-like growth factor I correlates with clearance Growth retardation and muscle protein catabolism are
in patients with chronic renal failure. common features in patients suffering from chronic renal
Background. Chronic renal failure (CRF) results in major failure (CRF), and numerous clinical as well as experi-
changes in the circulating growth hormone (GH)/insulin-like mental studies suggest abnormalities in the growth hor-
growth factor (IGF) system. However, there are only limited
mone (GH)/insulin-like growth factor (IGF) system todata on changes in free IGF-I in CRF.
play a key role [1, 2]. Patients with CRF have elevatedMethods. Matched groups of nondiabetic, nondialyzed pa-
serum levels of GH [3] that appear to be a consequencetients with CRF (N 5 25) and healthy controls (N 5 13) were
compared. The creatinine clearance (CCr) based on a 24-hour of an increased secretion rate and reduced metabolic
urine collection ranged from 3 to 59 and 89 to 148 ml/min/1.73 m2 clearance rate (MCR) [2, 4, 5]. Concomitantly, CRF is
in patients and controls, respectively. Overnight fasting serum characterized by reduced circulating levels of the high-
samples were analyzed for free and total IGF-I and -II, and affinity GH-binding protein (GHBP), which has been
IGF-binding protein (IGFBP)-1, -2, and -3. Additionally, intact used as an indicator of the hepatic GH receptor densityas well as proteolyzed IGFBP-3 was determined.
[6]. The GH hypersecretion in CRF is therefore believedResults. The patients had reduced serum-free IGF-I (253%)
to reflect a state of hepatic GH resistance [2].and increased levels of total IGF-II (40%), IGFBP-1 (546%),
In addition to GH resistance, the bioactivity measuredand IGFBP-2 (270%, P , 0.05). Serum total IGF-I and free
IGF-II were normal. Also, serum levels of immunoreactive in vitro of the IGF system appears to be reduced in CRF
IGFBP-3 were elevated (33%, P , 0.05), but this could be [7–9]. Because levels of serum total (extractable) IGF-I
explained by an increased abundance of IGFBP-3 fragments, are usually within the normal range [1], interest has fo-
as ligand blotting showed no difference in levels of intact cused on changes in the circulating levels of the IGF-
IGFBP-3. Accordingly, patients had an increased proteolysis
binding proteins (IGFBPs) [7, 8]. Thus, patients withof IGFBP-3 in vivo (17%) and in vitro (7%, P , 0.05). In
CRF have elevated serum levels of IGFBP-1, IGFBP-2,patients, free IGF-I levels correlated positively with CCr (r 2 5
and IGFBP-4 [10, 11], which are all predominantly inhib-0.38, P , 0.002) and inversely with IGFBP-1 (r 2 5 0.69, P ,
0.0001) and IGFBP-2 (r 2 5 0.41, P , 0.0007), whereas CCr was itory to the actions of IGF-I [12, 13]. Additionally, CRF
inversely correlated with levels of IGFBP-1 (r 2 5 0.48, P , is associated with elevated serum levels of low molecular
0.0001) and IGFBP-2 (r 2 5 0.63, P , 0.0001). fragments of IGFBP-3, some of which have retained the
Conclusions. These data strongly support the hypothesis ability to bind IGF-I, albeit with lower affinity [14]. The
that CRF-related growth failure and tissue catabolism are accumulation of circulating IGFBPs and IGFBP frag-caused by an increased concentration of circulating IGFBP-1
ments is believed to play a central role in the growthand -2, resulting in low serum levels of free IGF-I and thus
abnormalities observed in patients with CRF, and thisIGF-I bioactivity. In addition, low levels of free IGF-I may
view has been supported by in vitro as well as in vivo data.explain the increased secretion of GH in CRF.
Blum et al showed that the removal of excess IGFBPs in
serum from patients with CRF normalized the in vitro
IGF-bioactivity [7], and To¨nshoff et al found an inverseKey words: growth hormone, tissue catabolism, end-stage renal failure,
creatinine clearance. correlation between height and serum levels of IGFBP-1
as well as IGFBP-2 in a cross-sectional study of prepu-Received for publication April 12, 1999
bertal children with CRF [10]. Taken together, theseand in revised form July 22, 1999
Accepted for publication August 3, 1999 observations strongly suggest that the circulating levels
of free and presumably bioactive IGF-I are reduced in 1999 by the International Society of Nephrology
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Table 1. Subject characteristics IGF system, patients were selected with a kidney func-
tion, expressed as CCr, ranging from incipient CRF toVariables Controls Patients P
overt ESRF, whereas all controls had a clearance aboveN 13 25
Males/females 8/5 18/7 NS 80 ml/min/1.73 m2 (Table 1). The healthy controls were
Age years 4662 5162 NS recruited among the hospital staff. They all underwent
BMI kg/m2 24.761.2 24.561.1 NS
routine physical examination and a biochemical screen-Creatinine clearance
ml/min/1.73 m2 (range) 11364 (89–148) 26 63 (3–59) ,0.0001 ing to preclude the presence of malignancy and infectious
Fasting serum glucose diseases. With the exception of oral contraceptives, none
mmol/liter 4.660.3 5.160.2 NS
of the healthy controls received any prescribed medica-Serum albumin g/liter 4461 3561 ,0.0001
tion. The study was approved by the local ethical commit-Data are mean 6 sem, and range when appropriate.
tee, and all subjects gave informed consent to participate.
Analytical determinations
Blood samples were collected after an overnight fast,CRF [7]. Low serum levels of free IGF-I may at the
same time contribute to the increased secretion of GH with medication being withdrawn from the night before
sampling. Serum was stored at 2208C. All measurementsand some of the growth abnormalities seen in patients
with CRF. were performed in duplicates within the same run unless
otherwise stated. IGF-I and -II were determined by in-The aim of this study was to test the hypothesis that
levels of free IGF-I are reduced in patients with CRF house noncompetitive monoclonal antibody-based time-
resolved immunofluorometric assays (TR-IFMAs), asand that this reduction is related to an accumulation
of circulating IGFBPs. We also wanted to investigate previously described [15]. These assays are characterized
by high sensitivity [the detection limit was 2.5 ng/literwhether the CRF-related changes in the IGF system are
associated with the severity of disease. Therefore, we (IGF-I) and 10 ng/liter (IGF-II)] and specificity (the
IGF-I and IGF-II cross reactivity in heterologous assaysselected the patients so that their kidney function, ex-
pressed as clearance of creatinine (CCr), ranged from was , 0.0002%).
Serum total (extractable) IGF-I and -II were deter-incipient CRF to overt end-stage renal failure (ESRF).
mined in acid ethanol serum extracts with a within assay
coefficient of variation (CV) averaging less than 5% [15].
METHODS
However, acid ethanol extraction may not always be
Subjects sufficient to remove the IGFBPs present in serum from
patients with severely affected kidney function (that is,The study included 25 nondiabetic patients with CRF
and 13 healthy controls matched for age, gender, and uremia) [16], and we therefore modified the extraction
procedure using the IGF-blocking principle originallybody mass index (BMI; Table 1). All patients were re-
cruited from the Department of Nephrology, Aarhus described by Blum, Ranke, and Bierich [17]. Thus, acid
ethanol serum extracts used for determination of IGF-IUniversity Hospital, Denmark. They were newly diag-
nosed, and none of the patients had received any treat- were neutralized in buffer containing an approximate
40-fold molar excess of IGF-II, whereas extracts usedment with dialysis prior to the time of blood sampling.
The presence of renal disease was based on routine phys- for IGF-II determinations were neutralized in buffer con-
taining an approximate 10-fold molar excess of IGF-I.ical examination, biochemical findings and renal biopsy,
histology, or, in the case of adult polycystic kidney dis- The same buffers were used for the respective calibration
curves, and they caused no cross-reaction.ease, ultrasound. The patients were diagnosed as having
glomerulonephritis (N 5 7), nephrosclerosis and hyper- Serum-free IGF-I and -II were determined using ultra-
filtration by centrifugation at conditions approachingtensive nephropathy (N 5 6), adult polycystic kidney
disease (N 5 6), interstitial nephropathy (N 5 3), IgA those in vivo [18]. Amicon YMT 30 membranes and
MPS-1 supporting devices were used (Amicon Division,nephritis (N 5 1), and unknown nephropathy (N 5 2).
Patients with CRF received oral treatment with loop Beverly, MA, USA). Before centrifugation, serum sam-
ples were diluted (1 in 11) in Krebs-Ringer bicarbonatediuretics (N 5 10), thiazides (N 5 7), calcium channel
antagonists (N 5 9), angiotensin-converting enzyme in- buffer (pH 7.4) containing 50 g/liter human serum albu-
min (Behring AG, Marburg, Germany). From each dilu-hibitors (N 5 10), b-blockers (N 5 10), vitamin D (N 5 2),
calcium carbonate (N 5 5), and erythropoietin (N 5 2). tion, triplicates of 600 ml were applied to the membranes
and incubated (30 min at 378C) and centrifuged (1500None of the patients had received recombinant human
(rh) GH, glucocorticoids, or immunosuppressive drugs. r.p.m. at 378C; model Rotixa/RP; Hettich Zentrifugen,
Tuttlingen, Germany). The lower detection limit of freeThe CCr was based on a 24-hour urine collection and
was expressed as ml/min/1.73 m2. In order to study the IGF-I and -II in the ultrafiltrates was 20 and 90 ng/liter,
respectively. Levels of free IGF-I and -II were analyzedrelationship between kidney function and changes in the
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in separate ultrafiltrates. Including ultrafiltration and im- Statistics
munoassay, the within assays CV averaged 18% and 12% Fisher’s exact test was used to compare the ratio of
for free IGF-I and -II, respectively. males versus females in the two groups. Patients and con-
Insulin-like growth factor-binding proteins were deter- trols were compared by use of Student’s unpaired t-test
mined by specific immunoassays, ligand blotting, and (parametric data) or the Mann–Whitney’s rank sum test
immunoblotting. Immunoreactive levels of IGFBP-1, -2, (nonparametric data). Linear regression analysis was
and -3 were determined by enzyme-linked immunosor- performed on log-transformed data to fulfill the criteria
bent assay (Medix Biochemica, Kainiainen, Finland), ra- for normality and variance homogeneity of the residuals.
dioimmunoassay, and immunoradiometric assay (IRMA), All data are given as mean 6 sem. A P value ,0.05 was
respectively (both Diagnostic System Laboratories Inc., considered statistically significant.
Webster, TX, USA). Sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and ligand blot-
RESULTSting were performed as originally described by Hossen-
The patients with CRF were characterized by in-lopp et al [19]. Two microliters of serum were subjected
creased fasting insulin (55%, P , 0.05; Fig. 1A) and GHto SDS-PAGE (10% polyacrylamide) under nonreduc-
(360%, P , 0.005; Fig. 1B) when compared with controls.ing conditions. rhIGF-I (Amersham, Buckinghamshire,
Still, the patients had normal fasting serum glucose (Ta-UK) was iodinated using the chloramine-T method and
ble 1). Serum albumin was reduced by 20% (P , 0.0001)served as ligand (approximately 100,000 CPM per sam-
in CRF when compared with controls (Table 1). Nople). The resulting autoradiograms were scanned using
significant difference in levels of serum total IGF-I wasa laser densitometer (Shimadzu model CS 90001PC; Shi-
observed (Fig. 1C), whereas serum total IGF-II was in-madzu Europe GmbH, Duisburg, Germany), and the
creased by 40% in the patients (P , 0.005; Fig. 1D).relative densities of the bands were expressed in arbi-
Serum-free IGF-I was markedly reduced in the patientstrary absorbency units per square millimeter (pixel den-
when compared with controls (190 6 30 vs. 400 6 50sity). Serum samples from controls and patients were
ng/liter, P , 0.0005; Fig. 1E), whereas no difference inequally distributed on the gels.
serum-free IGF-II was observed (patients vs. controls:In addition to determination of IGFBP-3 by immuno-
1220 6 110 vs. 1110 6 50 ng/liter; Fig. 1F).assay (immunoreactive IGFBP-3) and ligand blotting (in-
The patients were characterized by highly elevatedtact 38 to 42 kDa IGFBP-3), we also estimated the in vivo
serum levels of immunoreactive IGFBP-1 (546%, P ,proteolysis of IGFBP-3 by immunoblotting performed
0.0001; Fig. 2A) and IGFBP-2 (270%, P , 0.0001; Fig.as previously described using a polyclonal IGFBP-3 anti-
2B). Also, serum levels of immunoreactive IGFBP-3
body (Upstate Biotechnology Inc., Lake Placid, NY,
were increased in the patients (33%, P , 0.001; Fig.
USA) [20]. The immunoblot yielded three distinct bands 2C). However, this may be explained by an increased
representing intact (38 to 42 kDa) and fragmented (16 concentration of small (16 and 30 kDa) immunoreactive
and 30 kDa) IGFBP-3 [20]. Based on the pixel density fragments of IGFBP-3 rather than elevated levels of
of these bands, the fraction of proteolyzed IGFBP-3 was intact IGFBP-3. Thus, the densities of intact 38 to 42
calculated as the ratio of fragmented IGFBP-3 (30 plus kDa IGFBP-3 determined by ligand blotting did not
16 kDa) divided by the sum of all three IGFBP-3 bands. differ between the two groups (Fig. 2D), whereas
In vitro proteolysis was performed as originally de- IGFBP-3 immunoblotting showed an increased density
scribed by Lamson, Giudice, and Rosenfeld [21] using of in vivo degraded IGFBP-3 in the patients (17%, P ,
iodinated rhIGFBP-3 (125I-rhIGFBP-3; Diagnostic System 0.001; Fig. 2E). Also, the in vitro degradation of IGFBP-3
Laboratories Inc.). Two microliters of serum were incu- was increased in the patients (7%, P , 0.05; Fig. 2F).
bated with approximately 30,000 CPM of 125I-rhIGFBP-3 In addition to the band at 38 to 42 kDa, which was
for 18 hours at 378C and were subjected to SDS-PAGE identified as IGFBP-3 by immunoblotting, ligand blot-
and autoradiography. Serum samples from a healthy ting yielded three other distinct bands with estimated
nonpregnant subject and a term-pregnant woman were molecular weights of 33, 29, and 24 kDa. These IGFBPs
included as internal controls. The fraction of degraded were not identified by immunoblotting, but in all cases,
125I-rhIGFBP-3 was calculated in the same way as de- the densities of the bands were markedly increased in
scribed earlier in this article, that is, as the ratio of the patients with CRF. Thus, the pixel densities were (pa-
density of fragmented 125I-rhIGFBP-3 divided by the sum tients vs. controls) 229 6 27 versus 59 6 9 (33 kDa, P ,
of all 125I-rhIGFBP-3–related densities. The in-between 0.0001), 82 6 11 versus 38 6 4 (29 kDa, P , 0.005), and
assay CV of the two control samples averaged 10%. 43 6 6 versus 24 6 2 (24 kDa, P , 0.005).
Insulin and GH were determined by commercial TR- We have previously identified the 29 kDa band as
IFMAs (Wallac Oy, Turku, Finland), and serum glucose IGFBP-2 by immunoblotting [22], and a highly signifi-
cant positive correlation was observed between serumwas determined by the glucose-oxidase method.
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Fig. 1. Fasting serum levels of insulin (A),
growth hormone (GH; B), total insulin-like
growth factor-I (IGF-I; C ), total IGF-II (D),
free IGF-I (E ), and free IGF-II (F ) in controls
(h) and patients (j). P values are indicated.
NS, not significant. Data are mean 6 sem.
levels of immunoreactive IGFBP-2 and the density of free IGF-I and total IGF-I, IGFBP-1 and IGFBP-2, re-
the 29 kDa band (r 2 5 0.72, P , 0.0001, N 5 38). Simi- spectively, whereas free IGF-I was independent of
larly, levels of immureactive IGFBP-1 correlated posi- IGFBP-3 proteolysis in vivo as well as in vitro. Multiple
tively with the density of the 29 kDa band (r 2 5 0.60, P , linear regression analysis on pooled data showed that the
0.0001, N 5 38), which most likely represents IGFBP-1 [1]. combination of total IGF-I, IGFBP-1, and IGFBP-2 could
Linear regression analysis was used to assess the rela- explain more than 75% of serum levels of free IGF-I (r 2 5
tionship between kidney function (that is, CCr) and the 0.78, P , 0.0001). Finally, in patients, levels of IGFBP-1
different members of the IGF system (Table 2 and Fig. and insulin were inversely correlated (Table 2).
3). In patients with CRF, CCr correlated inversely with
serum levels of IGFBP-1 and IGFBP-2 and positively
DISCUSSIONwith serum-free IGF-I (Table 2 and Fig. 3). An inverse
To study the impact of CRF on the circulating levelscorrelation between CCr and the proteolysis of IGFBP-3
of free IGF-I and its regulatory proteins, we comparedin vivo and in vitro was also observed (Table 2). Similar
adult patients with CRF who had received no treatmentobservations were made when the two groups were
with dialysis, and sex-, age- and BMI-matched controls.pooled (Table 2 and Fig. 3), whereas in controls, CCr
The study showed that adult patients with CRF hadcorrelated significantly only with serum IGFBP-2. Sig-
nificant correlations were observed between levels of reduced overnight fasting serum levels of free IGF-I and
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Fig. 2. Fasting serum levels of insulin-like
growth factor binding protein (IGFBP)-1 (A),
IGFBP-2 (B), and IGFBP-3 (C ) determined
by specific immunoassays in controls (h) and
patients (j). The concentration of intact 38
to 42 kDa IGFBP-3 was also determined by
ligand blotting (D). IGFBP-3 immunoblotting
was used to estimate the fraction of in vivo
degraded IGFBP-3 in serum (E). An IGFBP-3
protease assay was used to estimate the in
vitro degradation of 125I-rhIGFBP-3 in serum
(F ). P values are indicated. NS, not significant.
Data are mean 6 sem.
Table 2. Linear regression analysis
Independent vs. dependent variable Controls (N 5 13) Patients (N 5 25) Both groups (N 5 38)
Clearance vs. IGFBP-1 NS P,0.0001, r 2 50.48 P,0.0001, r 2 50.69
Clearance vs. IGFBP-2 P,0.02, r 2 50.46 P,0.0001, r 2 50.63 P,0.0001, r 2 50.80
Clearance vs. free IGF-I NS P,0.002, r 2 50.38 P,0.0001, r 2 50.50
Clearance vs. IGFBP-3 in vivo degradationa NS P,0.0005, r 2 50.45 P,0.0001, r 2 50.60
Clearance vs. IGFBP-3 in vitro degradationa NS P,0.05, r 2 50.17 P,0.002, r 2 50.25
Insulin vs. IGFBP-1 NS P,0.0005, r 2 50.41 NS
IGFBP-1 vs. free IGF-I NS P,0.0001, r 2 50.69 P,0.0001, r 2 50.68
IGFBP-2 vs. free IGF-I P,0.03, r 2 50.34 P,0.0007, r 2 50.41 P,0.0001, r 2 50.50
Total IGF-I vs. free IGF-I P,0.005, r 2 50.54 P,0.01, r 2 50.29 P,0.02, r 2 50.15
IGFBP-3 in vivo degradation vs. free IGF-I NS NS P,0.007, r 2 50.20
IGFBP-3 in vitro degradation vs. free IGF-I NS NS P,0.02, r 2 50.15
All data were log transformed prior to analysis to improve normality and variance homogeneity.
Abbreviations are: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; NS, not significant.
a Due to the limited capacity of the gels, the number of samples was reduced to 12 (controls) and 24 (patients); the two omitted samples were randomly selected
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increased levels of intact IGFBP-1 and -2. Also, serum
levels of IGFBP-3 were increased, but this could be ex-
plained by an elevated concentration of IGFBP-3 frag-
ments, as the density of intact IGFBP-3 was unchanged.
Accordingly, patients with CRF showed a significantly
increased in vivo and in vitro proteolysis of IGFBP-3.
However, this appeared to be without any significance
for levels of free IGF-I. Instead, more than 75% of the
variance in serum-free IGF-I in CRF could be predicted
from a linear combination of levels of IGFBP-1, IGFBP-2,
and total IGF-I. It is noteworthy that the kidney function,
expressed as CCr, correlated positively with free IGF-I
and inversely with IGFBP-1 and -2. Finally, levels of
free IGF-II remained within the normal range in CRF,
whereas serum total IGF-II was significantly elevated.
In our study, serum-free IGF-I was determined by
ultrafiltration at conditions approaching those in vivo,
that is, at 378C and pH 7.4 [18], and employing this
technique, we observed a reduction of more than 50%
in serum levels of free IGF-I in patients with CRF. This
observation is different from two previous studies. Rab-
kin et al compared serum levels of free (plus readily
dissociable) IGF-I in groups of adults (N 5 6) with CRF
and matched healthy controls before and after a subcuta-
neous injection of rhIGF-I (80 mg/kg) [23]. However,
they failed to observe any significant difference in either
baseline levels or in the increase in free IGF-I following
injection, despite elevated serum IGFBP levels in CRF.
Bereket et al compared serum levels of free (plus readily
dissociable) IGF-I in children with ESRF (N 5 5) before
and after one year of GH treatment [24]. Although levels
increased approximately 2.5-fold following GH therapy,
the pretreatment level of free IGF-I was not significantly
different from that of matched controls. Most likely, the
discrepancy between our findings and those of Rabkin
et al and Bereket et al is explained by the use of different
assays for free IGF-I [23, 24]. Thus, both said investiga-
tions employed a commercially available IRMA based
on an immobilized antibody directed against free IGF-I
(obtained from Diagnostic System Laboratories Inc.)
[23, 24]. This assay is performed by incubating serum
samples directly in antibody-coated test tubes for two
hours at 58C. After incubation and wash, a second 125I-
labeled IGF-I antibody was used for detection. The
IRMA is believed to overestimate the concentration of
free IGF-I, as the solid-phase antibody most likely ex-
tracts some “loosely bound” IGF-I from the low affinity
IGFBPs or IGFBP fragments [23]. In the case of CRF,
Fig. 3. Linear regressions between creatinine clearance and serum lev- the concentration of low molecular IGFBP-3 fragments
els of IGFBP-1 (A), IGFBP-2 (B), and free IGF-I (C ). Please note the is significantly increased [2], and although some of themlog scales of the X and Y axes. The regression lines are based on pooled
are still able to bind IGF-I, the affinity is much lowerdata of controls (s) and patients (d). P and r values are indicated.
than that of intact IGFBP-3 [14, 25, 26]. Therefore, in
abnormal situations such as CRF, the IRMA may yield
erroneously high levels of free IGF-I.
Patients with CRF are usually characterized by in-
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creased serum levels of GH [2, 3], and accordingly, we related growth inhibition is at least partly related to an
imbalance between free IGF-I and IGFBP-1 and -2.observed an approximate fourfold increase in overnight
fasting serum levels of GH in patients with CRF. Veld- Although our data suggest IGFBP-1 and -2 to play a
central role in the regulation of free IGF-I in renal dis-huis et al compared by deconvolution analysis the spon-
taneous 24-hour secretion of GH in adult men with he- ease, we cannot preclude that a reduced production rate
of IGF-I may also participate. In support of an impairedmodialysis dependent ESRF and healthy controls and
observed an increased daily secretion rate as well as protein synthesis in CRF, we observed a 20% reduction
in serum albumin levels. However, studies of the impactprolonged half-life in ESRF [5]. These observations are
in agreement with findings in patients with CRF follow- of renal disease on the synthesis of IGF-I have been
ambiguous. Thus, based on a mathematical model, Bluming intravenous administration of rhGH, which addition-
ally showed that the MCR of rhGH was reduced by et al estimated the IGF-I production rate to be reduced
by an order of magnitude in children with CRF [7].approximately 50% when compared with controls [4].
Furthermore, serum GHBP, which has been used as an This idea has been supported by experimental studies
in uremic rats showing a 60% reduction in the hepaticestimate of cellular GH receptor density, is reduced in
CRF [2, 6]. Thus, it has been hypothesized that the CRF- IGF-I mRNA expression [29], whereas pharmacokinetic
studies in humans have failed to show any difference inrelated hypersomatropinemia is caused by a reduced re-
nal GH clearance and a relative insensitivity to the ac- the calculated IGF-I production rate [23]. Finally, changes
in the renal excretion rate of free IGF-I may be of impor-tions of GH. However, an attenuated negative feedback
regulation of IGF-I on the pituitary may also be involved tance. Studies in patients with nephrotic syndrome have
shown an increased urinary excretion rate of IGFBP-1[5], and in this context, we find it noteworthy that levels
of free but not total IGF-I were markedly decreased and -2 [30], and the same may be true for free IGF-I.
However, in this study, neither serum albumin nor thein patients with CRF. A recent study in healthy adults
indicated that free rather than bound IGF-I was involved 24-hour urinary protein excretion rate was significantly
correlated with serum levels of free IGF-I (P valuesin the feedback inhibition of GH secretion [27]. Assum-
ing this is also true in patients with CRF, our findings larger than 0.25; data not shown).
The kidneys are believed to play an important roleof reduced levels of free IGF-I provide a simple explana-
tion for the increased secretion of GH in CRF. in the removal of circulating peptides and an impaired
kidney function may therefore explain the elevated circu-In patients with CRF, more than 75% of the variation
in serum-free IGF-I could be predicted statistically by a lating IGFBP levels in CRF. Supportive of this, we ob-
served strong inverse correlations between CCr and serumlinear combination of levels of total IGF-I, IGFBP-1, and
IGFBP-2, whereas intact as well as proteolyzed IGFBP-3 levels of IGFBP-1 and -2, and similar observations were
made in children with CRF [10]. On the other hand,failed to show any significant relationship with free
IGF-I. Furthermore, CCr correlated positively with serum experiments in uremic rats showed markedly elevated
IGFBP-1 and -2 serum peptide and liver mRNA levels,free IGF-I and inversely with IGFBP-1 and -2. Thus,
these data strongly support the hypothesis that CRF- suggesting that an increased IGFBP production was also
involved [29]. In this context, we observed an inverserelated growth failure and tissue catabolism are partly
caused by an increased concentration of circulating relationship between IGFBP-1 and serum insulin, indicat-
ing that the physiological association between these twoIGFBP-1 and -2, resulting in low serum levels of free
IGF-I and thus IGF-I bioactivity. Furthermore, we find peptides is maintained in a hyperinsulinemic and insulin-
resistant condition such as CRF [3, 13, 31]. Thus, thethese results interesting in view of clinical observations
in children. Thus, more than 20 years ago, Schwalbe et increased levels of IGFBP-1 and -2 may not merely be
secondary to changes in the renal handling of peptides.al showed that in serum from children with CRF, the
IGF bioactivity in vitro correlated positively with growth In our study, patients with CRF showed an increased
abundance of circulating low molecular IGFBP-3 frag-velocity and glomerular filtration rate (GFR) [9]. Re-
cently, To¨nshoff et al found an inverse relationship be- ments, whereas levels of intact IGFBP-3 did not differ
from controls. This observation is in accordance withtween height sd and serum levels of IGFBP-1 and
IGFBP-2, respectively, in prepubertal children with CRF, previous studies in CRF [2, 7, 32, 33]. Previous studies
have failed to detect any significant IGFBP-3 proteolysiswhereas levels of IGFBP-3 did not correlate with height
[10]. Powell et al studied changes in IGFBPs in children in vitro in serum from patients with CRF, and therefore,
the accumulation of IGFBP-3 fragments has been sug-with CRF before and after 12 months of treatment with
rhGH, and based on the observed increment in height, gested to result from reduced renal clearance [2, 32, 33].
However, in this study, the in vitro degradation of 125I-they suggested that IGFBP-3, in contrast to IGFBP-2,
was not likely to be a growth inhibitor [28]. The strong rhIGFBP-3 was significantly increased and inversely cor-
related with CCr in patients with CRF. This discrepancycoincidence between these studies and ours may be con-
sidered as an indirect support for the idea that the CRF- may be explained by differences in the selection of pa-
Frystyk et al: Free IGF-I in CRF 2083
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